Brief: Frequency Therapeutics Reports Unaudited Cash, Cash Equivalents, Marketable Securities $160.5 Million
Nov 9 (Reuters) - Frequency Therapeutics Inc FREQ.O :
* FREQUENCY THERAPEUTICS-UNAUDITED CASH, CASH EQUIVALENTS,
MARKETABLE SECURITIES $160.5 MILLION AS OF SEPT 30, 2021, WHICH
DOES NOT INCLUDE RESTRICTED CASH
Source text: [https://bit.ly/3F3g783]
Further company coverage: FREQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Korro Bio
See all newsBrief: Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Korro Announces First Cohort Dosed In Phase 1/2 Clinical Trial (Anchor) For Krro-121
Brief: Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Korro Bio, Inc. reports results for the quarter ended June 30 - Earnings Summary
Korro Bio, Inc. expected to post a loss of $1.43 a share - Earnings Preview